Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH).

ABSTRACT: Corticotropin-releasing factor (CRF) is a key neuropeptide hormone that is secreted from the hypothalamus. It is the master hormone of the HPA axis, which orchestrates the physiological and behavioral responses to stress. Many disorders, including anxiety, depression, addiction relapse, and others, are related to over-activation of this system. Thus, new molecules that may interfere with CRF receptor binding may be of value to treat neuropsychiatric stress-related disorders. Also, CRF₁R antagonists have recently emerged as potential treatment options for congenital adrenal hyperplasia. Previously, several series of CRF₁ receptor antagonists were developed by our group. In continuation of our efforts in this direction, herein we report the synthesis and biological eval

SUBMITTER: Islam MR 

PROVIDER: S-EPMC11314199 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature